Meet our community and take part in MI!
The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
AMU, AP-HM, CIML
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
As such, we are involved in the Marseille immunology biotope
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
AMU, AP-HM, CIML, INNATE PHARMA
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
AMU, IPC, AP-HM, Inserm
Education is also one of the strategic components of the Marseille Immunopole project
AMU, AP-HM, VRCM
Today, Marseille Immunopôle and their experts and platforms provide an outstanding multidisciplinary scientific environment for thoracic immuno-oncology research.
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
CCI Marseille Provence
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
AMU, IPC, CRCM
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
AMU, IPC, CRCM
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.
A therapeutic revolution is happening.
CIML, Canceropôle PACA
HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.